Cargando…

Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry: Trends in antithrombotic therapy use in China

BACKGROUND: Stroke prevention with oral anticoagulant (OAC) therapy, including non-vitamin K antagonist oral anticoagulants (NOACs), is recommended in patients with atrial fibrillation (AF). This analysis describes the antithrombotic prescription patterns for Chinese patients enrolled post-dabigatra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoxia, Feng, Guoze, Marler, Sabrina Vogel, Huisman, Menno V, Lip, Gregory Y. H., Ma, Changsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394786/ https://www.ncbi.nlm.nih.gov/pubmed/37528405 http://dx.doi.org/10.1186/s12959-023-00527-x

Ejemplares similares

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)

Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
por: Beier, Lea, et al.
Publicado: (2022)

Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017)

Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program
por: Azar, Rabih R., et al.
Publicado: (2021)

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020)

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
por: Huisman, Menno V., et al.
Publicado: (2016)

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry
por: Dubner, Sergio, et al.
Publicado: (2020)

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry
por: Apenteng, Patricia N, et al.
Publicado: (2018)

Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
por: McIntyre, William F., et al.
Publicado: (2018)

Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA‐AF Phase III Registry
por: Bayer, Valentina, et al.
Publicado: (2022)

Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community
por: Joosten, L. P. T., et al.
Publicado: (2022)

Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2022)

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2023)

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
por: Huisman, Menno V., et al.
Publicado: (2022)

Time‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT Registry
por: Boivin‐Proulx, Laurie‐Anne, et al.
Publicado: (2019)

Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registry
por: Sayın, Begüm Yetiş, et al.
Publicado: (2019)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020)

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021)

Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry
por: Dong, Zhimin, et al.
Publicado: (2022)

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020)

Temporal Trends of Antithrombotic Therapy in Patients With Acute Myocardial Infarction and Atrial Fibrillation: Insight From the KAMIR-NIH Registry
por: Lee, Oh-Hyun, et al.
Publicado: (2021)

Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry
por: Pope, Marita Knudsen, et al.
Publicado: (2021)

Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry
por: Winijkul, Arjbordin, et al.
Publicado: (2021)

Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation
por: Chu, Gordon, et al.
Publicado: (2020)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Atrial fibrillation in patients with first-ever stroke: Incidence trends and antithrombotic therapy before the event
por: Jung, Yo Han, et al.
Publicado: (2018)

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
por: Kakkar, Ajay K., et al.
Publicado: (2013)

Survey of Antithrombotic Treatment in Rural Patients (>60 years) with Atrial Fibrillation in East China
por: Wei, Yong, et al.
Publicado: (2018)

Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
por: Tzeis, Stylianos, et al.
Publicado: (2020)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs
por: Nielsen, Peter Brønnum, et al.
Publicado: (2021)

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
por: Abrignani, Maurizio Giuseppe, et al.
Publicado: (2022)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Comment from Huisman et al.
por: Huisman, Menno V., et al.
Publicado: (2022)

Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study
por: Valle, Felipe H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nkabfq8vkl829988mkq4f4cd1n